News › Clinical Practice, Industry News, Patient Care

Allergan Launches Juvéderm® VOLITE

January 27, 2017

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, announced today its entry into the skin quality category with the launch of Juvéderm® VOLITE. This is Allergan’s first injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session.This innovative new Allergan product uses the unique patented VYCROSS® technology.
A new innovation for skin quality 
The new HA injectable treatment delivers improvements in skin smoothness (absence of fine lines), hydration and elasticity, and is designed to last for up to nine months with just one treatment. Clinical data so far has shown significant improvements in skin quality for up to 6 months, and the clinical study is ongoing. Juvéderm® VOLITE aims to deliver results that last and eliminate the need for multiple treatments. It should be injected intradermally and can be used to treat the face, neck, décolletage and hands and contains the anaesthetic lidocaine, to enhance patient comfort.
Read more at PRNewswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • The Beauty Health Company (SKIN) Rebrands to SkinHealth Systems
    • Amazon Launches GLP-1 Weight Loss Program with One Medical
    • Botox Cosmetic’s “The Confidence Collective” to Empower 250 Women Entrepreneurs
    • Medical Spa Show 2027 Call for Presentations Now Open
    • FDA Warning Letter to Texas Medical Spa Signals Increased Compliance Enforcement